MA47331A - Compositions et procédés pour la déplétion des cellules cd137+ - Google Patents

Compositions et procédés pour la déplétion des cellules cd137+

Info

Publication number
MA47331A
MA47331A MA047331A MA47331A MA47331A MA 47331 A MA47331 A MA 47331A MA 047331 A MA047331 A MA 047331A MA 47331 A MA47331 A MA 47331A MA 47331 A MA47331 A MA 47331A
Authority
MA
Morocco
Prior art keywords
deletion
compositions
cells
methods
Prior art date
Application number
MA047331A
Other languages
English (en)
French (fr)
Inventor
Anthony Boitano
Michael Cooke
Adam Hartigan
Megan D Hoban
Rahul Palchaudhuri
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of MA47331A publication Critical patent/MA47331A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047331A 2017-01-20 2018-01-19 Compositions et procédés pour la déplétion des cellules cd137+ MA47331A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448741P 2017-01-20 2017-01-20
US201762595977P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
MA47331A true MA47331A (fr) 2019-11-27

Family

ID=62907802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047331A MA47331A (fr) 2017-01-20 2018-01-19 Compositions et procédés pour la déplétion des cellules cd137+

Country Status (14)

Country Link
US (3) US10576161B2 (enExample)
EP (1) EP3571230A4 (enExample)
JP (2) JP7256744B2 (enExample)
KR (2) KR102725761B1 (enExample)
CN (1) CN110461876B (enExample)
AU (1) AU2018209452B2 (enExample)
BR (1) BR112019014991A2 (enExample)
CA (1) CA3049501A1 (enExample)
IL (1) IL268058B2 (enExample)
MA (1) MA47331A (enExample)
MX (2) MX395639B (enExample)
SG (2) SG11201906319XA (enExample)
TW (1) TWI825007B (enExample)
WO (1) WO2018134787A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522050A (ja) 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 細胞の枯渇のための組成物および方法
US10576161B2 (en) * 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
KR20200094181A (ko) 2017-11-29 2020-08-06 마젠타 테라퓨틱스 인코포레이티드 Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
US12133884B2 (en) 2018-05-11 2024-11-05 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP2021532116A (ja) * 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
AU2019310430A1 (en) * 2018-07-23 2021-02-25 Magenta Therapeutics, Inc. Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy
AU2019312200B2 (en) * 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
AU2020223060B2 (en) 2019-02-13 2023-04-13 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020216947A1 (en) * 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
JP7682102B2 (ja) * 2019-05-10 2025-05-23 リビジェン バイオファーマ ホールディングス リミテッド ヒト化抗ｃｄ１３７抗体およびその使用
EP3980034A4 (en) * 2019-06-05 2024-02-28 Heidelberg Pharma Research GmbH T CELL DEPLETION THERAPIES
BR112022002953A2 (pt) * 2019-08-29 2022-05-17 Beam Therapeutics Inc Composições e métodos para condicionamento não tóxico
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
US20240058387A1 (en) * 2020-12-28 2024-02-22 Edigene (Guangzhou) Inc. Culture medium composition for amplifying and maintaining self-renewal capacity and differentiation potential of hscs and application thereof
CN117241832A (zh) 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
CN114369581B (zh) * 2021-12-30 2023-10-20 杭州医学院 一种具有抗肿瘤免疫功能重组腺病毒、制备方法及应用
WO2025128002A1 (en) * 2023-12-15 2025-06-19 National University Of Singapore Anti-cd137 antibody and the use thereof

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5451575A (en) 1988-02-19 1995-09-19 J. W. Broadbent Nominees Pty., Ltd. Method of treating liver dysfunction with 24-R scymnol
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
AU5186090A (en) 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
US5786457A (en) 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
ATE169031T1 (de) 1991-04-05 1998-08-15 Univ Washington Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
WO1993015751A1 (en) 1992-02-14 1993-08-19 Merck & Co., Inc. CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR
WO1994025621A1 (en) 1993-04-30 1994-11-10 Lxr Biotechnology Inc. Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
DE69435261D1 (de) 1993-09-16 2010-02-25 Univ Indiana Res & Tech Corp Menschlicher rezeptor h4-1bb
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
AU5369996A (en) 1995-03-23 1996-10-08 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
JP2911056B2 (ja) 1995-04-08 1999-06-23 株式会社エルジ化学 ヒト４−１ｂｂに特異的なモノクローナル抗体およびこれを産生する細胞株
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
CA2268340A1 (en) 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
AU6954398A (en) 1997-04-11 1998-11-11 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
US20030096976A1 (en) 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
KR20000034847A (ko) 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
AU2951599A (en) 1999-04-08 2000-11-14 Pavel Sergeev Synthesis of biologically active compounds in cells
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AU4985201A (en) 2000-10-18 2002-04-29 Us Gov Health & Human Serv Human gene critical to fertility
JP2004536555A (ja) 2000-11-03 2004-12-09 ダナ ファーバー キャンサー インスティテュート 癌感受性の診断のための方法及び組成物並びに欠損ｄｎａ修復メカニズム及びその処置
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003048327A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
US7183385B2 (en) 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US20030232369A1 (en) 2002-04-17 2003-12-18 Bushnell David A. Molecular structure of RNA polymerase II
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
DE10219866A1 (de) 2002-05-03 2003-11-20 Isolde Riede-Kainrath Tumorprävention und Therapie durch Modifikation von "switch"-Genen oder RNA-Polymerase II-Aktivität
US6887673B2 (en) 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US20060121030A1 (en) 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
KR100500283B1 (ko) * 2003-03-25 2005-07-11 이뮤노믹스 주식회사 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20060014197A1 (en) 2004-07-15 2006-01-19 Wisconsin Alumni Research Foundation In vivo screening methods for identifying inhibitors of RNA polymerases
AU2005274852B2 (en) 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
EP1661584A1 (en) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
WO2007092196A2 (en) 2006-01-27 2007-08-16 Cellerant Therapeutics, Inc. Compositions and methods for treating myeloid proliferative disorders
CA2645347A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
CN103694349A (zh) * 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
PL3255061T3 (pl) 2006-11-03 2021-12-06 The Board Of Trustees Of The Leland Stanford Junior University Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US20100093008A1 (en) 2007-03-02 2010-04-15 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 (tyr969) and uses thereof
KR20080107050A (ko) * 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
US20110229460A1 (en) 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
EP3192529B1 (en) * 2009-04-08 2020-03-25 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
EP2416805B1 (en) * 2009-04-08 2013-07-24 Heinz Dr. Faulstich Amatoxin antibody conjugates for the treatment of cancer
US20120076722A1 (en) 2009-05-14 2012-03-29 University Of Maryland, Baltimore Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
EP2266964B1 (en) * 2009-06-22 2013-01-09 KTB Tumorforschungsgesellschaft mbH Acid-labile trigger units
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US9023996B2 (en) 2009-12-23 2015-05-05 Synimmune Gmbh Anti-FLT3 antibodies
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
KR20110085038A (ko) * 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
AU2011312776B2 (en) 2010-07-13 2016-09-29 University Of Rhode Island Board Of Trustees Environmentally sensitive compositions
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
WO2012084895A2 (en) 2010-12-20 2012-06-28 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP2497499A1 (en) * 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
BR122020001787A8 (pt) 2011-05-08 2023-04-25 Legochem Biosciences Inc Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US10434121B2 (en) 2011-12-22 2019-10-08 Yeda Research And Development Co. Ltd. Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2849797B1 (en) 2012-05-15 2019-12-18 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
WO2014043403A1 (en) 2012-09-12 2014-03-20 Agensys, Inc. Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
BR112015006368B1 (pt) 2012-09-24 2022-02-08 Medimmune Limited Processo para produção de linha celular eucariótica estável
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
HK1212618A1 (zh) 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
WO2014134539A1 (en) 2013-02-28 2014-09-04 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
MX366978B (es) 2013-03-15 2019-08-01 Novartis Ag Conjugados de anticuerpo - farmaco.
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
KR20160006168A (ko) 2013-03-18 2016-01-18 바이오서오엑스 프로덕스 비.브이. 인간화 항-cd134(ox40) 항체 및 이의 용도
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US10071170B2 (en) 2013-06-24 2018-09-11 Ablbio Antibody-drug conjugate having improved stability and use thereof
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
JP6439690B2 (ja) 2013-07-12 2018-12-19 石原産業株式会社 細胞への遺伝子導入用組成物
JP6441949B6 (ja) 2013-11-05 2019-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ヒト中和抗ｋｉｔ抗体及びその使用
KR20150055655A (ko) 2013-11-13 2015-05-22 삼성디스플레이 주식회사 기판 세정 장치
EP3129407A2 (en) 2014-03-12 2017-02-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
JP6800021B2 (ja) 2014-06-02 2020-12-16 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
EP3174902B1 (en) 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
ES2945588T3 (es) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
WO2016036334A1 (en) 2014-09-03 2016-03-10 Şahi̇n Yücel Voltametric methods to determine alpha-amanitin and phalloidin
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
US20190209704A1 (en) 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use
WO2016071856A1 (en) * 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
EA201790871A1 (ru) 2014-11-11 2017-11-30 Амуникс Оперэйтинг Инк. Нацеленные конъюгатные композиции xten и способы их получения
EP3026060A1 (en) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
HRP20191824T1 (hr) 2015-01-08 2020-01-24 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
KR20240091253A (ko) 2015-02-16 2024-06-21 론자 리미티드 Cl 및/또는 ch1 돌연변이된 약물 접합용 항체
DK3265565T3 (da) 2015-03-04 2020-11-09 Univ Texas Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53
US9974865B2 (en) 2015-03-09 2018-05-22 Agensys, Inc. Antibody drug conjugates (ADC) that bind to FLT3 proteins
PT3268047T (pt) 2015-03-09 2023-12-05 Heidelberg Pharma Res Gmbh Conjugados amatoxina-anticorpo
WO2016145014A1 (en) 2015-03-10 2016-09-15 President And Fellows Of Harvard College Methods for treatment of autism spectrum disorders
WO2016164502A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
US10683506B2 (en) 2015-04-10 2020-06-16 The Methodist Hospital System CD117 ligand-drug conjugates for targeted cancer therapy
WO2016168471A1 (en) 2015-04-17 2016-10-20 Endocyte, Inc. Dual disulfide drug conjugates
EP3297647A1 (en) 2015-05-18 2018-03-28 Universidade Do Porto Use of polymyxin as an antidote for intoxications by amatoxins
US10806808B2 (en) 2015-05-22 2020-10-20 Memorial Sloan Kettering Cancer Center Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
WO2017004127A1 (en) 2015-06-29 2017-01-05 The General Hospital Corporation Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
JP2018523471A (ja) 2015-07-16 2018-08-23 セレラント セラピューティクス インコーポレイテッド システイン置換免疫グロブリン
US10660954B2 (en) 2015-07-31 2020-05-26 University Of Florida Research Foundation, Incorporated Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
CN108368511B (zh) 2015-10-23 2022-12-06 阿珀吉科吉尼科斯股份公司 单链cd137受体激动剂蛋白
JP2018536666A (ja) 2015-11-27 2018-12-13 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング γ−アマニチンの誘導体
CA3013412C (en) * 2016-02-04 2023-10-10 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
KR102295190B1 (ko) 2016-04-20 2021-08-30 항저우 디에이씨 바이오테크 씨오, 엘티디 아마니타 독소의 유도체 및 세포 결합 분자와의 그것의 결합
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
EP3471771A4 (en) 2016-05-31 2020-04-15 Sorrento Therapeutics, Inc. ANTIBODY CONJUGATES HAVING AMATOXIN DERIVATIVES AS A MEDICINAL PRODUCT
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
PT3558390T (pt) 2016-12-23 2024-10-29 Heidelberg Pharma Res Gmbh Conjugados amanitina anticorpo
US10576161B2 (en) * 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
EP3661938B1 (en) 2017-08-07 2025-01-15 Heidelberg Pharma Research GmbH Novel method for synthesizing amanitins

Also Published As

Publication number Publication date
BR112019014991A2 (pt) 2020-04-07
CA3049501A1 (en) 2018-07-26
JP2023093500A (ja) 2023-07-04
MX2019008205A (es) 2020-01-23
MX395639B (es) 2025-03-25
US10576161B2 (en) 2020-03-03
KR20190107097A (ko) 2019-09-18
IL268058B1 (en) 2023-05-01
EP3571230A2 (en) 2019-11-27
TW201833134A (zh) 2018-09-16
AU2018209452B2 (en) 2024-11-07
SG11201906319XA (en) 2019-08-27
JP7256744B2 (ja) 2023-04-12
US20200289664A1 (en) 2020-09-17
IL268058B2 (en) 2023-09-01
EP3571230A4 (en) 2020-12-16
JP2020506176A (ja) 2020-02-27
WO2018134787A2 (en) 2018-07-26
KR102725761B1 (ko) 2024-11-04
US10434185B2 (en) 2019-10-08
IL268058A (en) 2019-09-26
SG10202102897PA (en) 2021-04-29
MX2022011546A (es) 2022-10-18
KR20240161216A (ko) 2024-11-12
AU2018209452A1 (en) 2019-07-18
TWI825007B (zh) 2023-12-11
CN110461876B (zh) 2024-05-17
WO2018134787A3 (en) 2018-10-04
US20190076548A1 (en) 2019-03-14
US20180289832A1 (en) 2018-10-11
CN110461876A (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
MA47331A (fr) Compositions et procédés pour la déplétion des cellules cd137+
EP3503901A4 (en) METHOD AND COMPOSITIONS FOR BACK MARKET CELLS
MA45408A (fr) Compositions et procédés pour la déplétion des cellules cd117+
EP3429603A4 (en) METHOD AND COMPOSITIONS RELATED TO THE EXPANSION OF HEMATOPOETIC STEM CELLS
EP3371301A4 (en) METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
EP3383411A4 (en) METHOD AND COMPOSITIONS RELATED TO CHONDRISOMES FROM CULTURED CELLS
SG11202104524YA (en) Compositions and methods for t cell engineering
MA45407A (fr) Compositions et méthodes de déplétion de cellules
EP3793579A4 (en) METHODS AND COMPOSITIONS FOR GENERATION OF ENDODERMAL LINEAGE AND BETA CELLS AND USES THEREOF
IL269334A (en) Improved t cell compositions and methods
EP3370741A4 (en) METHOD AND COMPOSITIONS FOR GENETIZING BLOOD-GENERATING STEM CELLS
MA50858A (fr) Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie
PL3194570T3 (pl) Sposoby i kompozycje do inżynierii genomowej w której pośredniczy nukleaza i korekty hematopoetycznych komórek macierzystych
SG10202109731YA (en) Compositions and methods for selective elimination and replacement of hematopoietic stem cells
MA49981A (fr) Procédés et compositions de préparation de cellules génétiquement modifiées
EP3619234A4 (en) COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPIES
EP3008170A4 (en) SC-CELLS AND COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
EP2970890A4 (en) COMPOSITIONS AND METHOD FOR THE REPRODUCTION AND BREEDING OF EPITHELIC STEM CELLS
MA49979A (fr) Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
EP3371314A4 (en) GENOMIC MANIPULATION OF PLURIPOTENTIAL CELLS
MA43943A (fr) Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
EP3230460A4 (en) Methods and compositions for selectively eliminating cells of interest
EP3472307A4 (en) Methods and compositions for potentiating stem cell therapies
EP2978419A4 (en) COMPOSITIONS FOR IMPROVING THE VITABILITY OF CELLS AND METHODS FOR USE THEREOF